Table 3.

Effect of very low dose cyclobenzaprine (VLD CBP) on FM symptoms.

	Last Observation Carried Forward (LOCF)					SD	LOCF p^*	VLD CBP vs Placebo
	Treatment	Baseline (SD)	Week 8 (SD)	Mean Change	% of Baseline	SD	LOCF p^*	Treatment p^**	% of Baseline
Musculoskeletal pain	VLD CBP	2.3 (1.2)	1.7 (1.2)	–0.6	–26.1	0.88	0.010^†	0.044^†	–18.2
	Placebo	2.1 (1.2)	2.1 (1.4)	0	0.0	0.83	1.000
Fatigue	VLD CBP	5.0 (1.3)	4.3 (1.5)	–0.7	–14.0	1.33	0.039^†	0.126	–12.4
	Placebo	4.7 (1.2)	4.9 (1.4)	0.2	4.3	1.82	0.647
Tenderness	VLD CBP	14.3 (5.6)	18.6 (9.5)	4.3	30.1	5.76	0.006^†	0.029^†	16.7
	Placebo	15.6 (10.1)	16.1 (7.7)	0.5	3.2	4.13	0.614
HAD score	VLD CBP	13.7 (5.8)	10.4 (7.5)	–3.3	–24.1	4.96	0.012^†	0.067	–32.0
	Placebo	15.7 (7.4)	15.1 (8.9)	–0.6	–3.8	3.36	0.459
HAD depression	VLD CBP	6.3 (3.9)	4.9 (4.5)	–1.4	–22.2	2.25	0.017^†	0.023^†	–38.5
	Placebo	6.7 (4.1)	7.4 (4.7)	0.7	10.4	2.89	0.319
Patient-rated change in fatigue	VLD CBP			2.9		1.00	0.001^†	0.133
	Placebo			2.5		1.29	0.120
Clinician-rated change in fatigue	VLD CBP			2.8		1.04	0.003^†	0.257
	Placebo			2.5		1.15	0.083

↵* Each t test is used to test that within-group change from baseline is significant, i.e., different from 0. p value is 2-sided.
↵** ANOVA p value comparing mean change from baseline between treatments.
↵† p ≤ 0.05. HAD: Hospital Anxiety and Depression Scale.